Spots Global Cancer Trial Database for non small cell lung carcinoma
Every month we try and update this database with for non small cell lung carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors | NCT01999738 | Solid Tumors Non Small Cell ... | EC1456 and EC20 | 18 Years - | Endocyte | |
| Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | NCT00080340 | Non Small Cell ... | TLK286 (Telcyta... gefitinib (Ires... | 18 Years - | Telik | |
| ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer | NCT00252798 | Non Small Cell ... | Gefitinib Carboplatin Paclitaxel Radiation | 18 Years - | AstraZeneca | |
| Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors | NCT01999738 | Solid Tumors Non Small Cell ... | EC1456 and EC20 | 18 Years - | Endocyte | |
| Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04427072 | Carcinoma, Non-... | Capmatinib Docetaxel | 18 Years - | Novartis | |
| Anti PD-1 Neo-adjuvant Treatment for NSCLC | NCT02938624 | Non Small Cell ... Stage I Stage II | Pembrolizumab 2... Pembrolizumab 2... Pembrolizumab 2... Pembrolizumab 1... Surgical resect... | 18 Years - 99 Years | Sheba Medical Center | |
| Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer | NCT01637376 | Carcinoma, Non-... | Temoporfin | 18 Years - | University of Arkansas | |
| Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... | NCT01229150 | Non Small Cell ... | AZD6244 Erlotinib AZD6244 + Erlot... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer | NCT00864266 | Non Small Cell ... | Chemotherapy | 18 Years - | European Lung Cancer Working Party | |
| ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer | NCT00252798 | Non Small Cell ... | Gefitinib Carboplatin Paclitaxel Radiation | 18 Years - | AstraZeneca | |
| Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04427072 | Carcinoma, Non-... | Capmatinib Docetaxel | 18 Years - | Novartis | |
| Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04427072 | Carcinoma, Non-... | Capmatinib Docetaxel | 18 Years - | Novartis | |
| LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer | NCT01685138 | Non-Small Cell ... | LDK378 | 18 Years - | Novartis | |
| LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. | NCT02450903 | Non-Small-Cell ... | LDK378 | 18 Years - | Novartis | |
| ZD6474 Phase IIa Dose Finding Multicentre Study | NCT00252746 | Non Small Cell ... | ZD6474 (vandeta... ZD6474 (vandeta... ZD6474 (vandeta... | 20 Years - | Sanofi | |
| Chemoradiotherapy in Patients With Localised Lung Cancer | NCT00193921 | Non Small Cell ... | Vinorelbine High dose Radio... Gemcitabine Cisplatin High Dose Radio... | 18 Years - | Trans Tasman Radiation Oncology Group | |
| Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer | NCT04507919 | Small Cell Lung... | Dabrafenib Trametininb | 18 Years - 99 Years | Novartis | |
| Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study. | NCT00759382 | Non Small Cell ... | 18 Years - | European Lung Cancer Working Party | ||
| Texture Features and PDL1 in CT-PET 18 FDG | NCT04309422 | Non Small Cell ... | 18 Years - | University Hospital, Montpellier | ||
| Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC) | NCT00890903 | Non Small Cell ... Metastatic Brea... | 18 Years - | Pierre Fabre Pharma GmbH | ||
| Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer | NCT06267144 | Lung Cancer | Sintilimab plus... | 18 Years - 75 Years | The First Hospital of Jilin University | |
| ZD6474 Phase IIa Dose Finding Multicentre Study | NCT00252746 | Non Small Cell ... | ZD6474 (vandeta... ZD6474 (vandeta... ZD6474 (vandeta... | 20 Years - | Sanofi | |
| Protocol for Primary Fractionated Stereotactic Body Radiation Therapy for Stage T1 - T3N0 Non Small Cell Lung Carcinoma. | NCT00727350 | Non Small Cell ... | Fractionated st... | 18 Years - | AZ-VUB | |
| A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer | NCT00087711 | Non Small Cell ... | pemetrexed gemcitabine cisplatin | 18 Years - | Eli Lilly and Company | |
| LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib | NCT01828112 | Non-Small Cell ... | Ceritinib pemetrexed docetaxel | 18 Years - | Novartis | |
| A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | NCT02974725 | Non-Small Cell ... Melanoma | LXH254 LTT462 Trametinib Ribociclib | 18 Years - | Novartis | |
| Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy | NCT00661011 | Non Small Cell ... | Lobectomy follo... | 18 Years - | European Lung Cancer Working Party | |
| Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... | NCT01229150 | Non Small Cell ... | AZD6244 Erlotinib AZD6244 + Erlot... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer | NCT00864266 | Non Small Cell ... | Chemotherapy | 18 Years - | European Lung Cancer Working Party | |
| Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC) | NCT04741789 | Carcinoma, Non-... Non-Small Cell ... Non-Small-Cell ... Nonsmall Cell L... | Capmatinib | 18 Years - 99 Years | Novartis | |
| Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC) | NCT00890903 | Non Small Cell ... Metastatic Brea... | 18 Years - | Pierre Fabre Pharma GmbH | ||
| Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC) | NCT04741789 | Carcinoma, Non-... Non-Small Cell ... Non-Small-Cell ... Nonsmall Cell L... | Capmatinib | 18 Years - 99 Years | Novartis | |
| LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer | NCT01828099 | Non-Small Cell ... | Ceritinib Pemetrexed Cisplatin Carboplatin | 18 Years - | Novartis | |
| Texture Features and PDL1 in CT-PET 18 FDG | NCT04309422 | Non Small Cell ... | 18 Years - | University Hospital, Montpellier | ||
| A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | NCT02974725 | Non-Small Cell ... Melanoma | LXH254 LTT462 Trametinib Ribociclib | 18 Years - | Novartis | |
| Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | NCT00080340 | Non Small Cell ... | TLK286 (Telcyta... gefitinib (Ires... | 18 Years - | Telik | |
| Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2 | NCT01836575 | Non Small Cell ... | Pemetrexed Carboplatin | 18 Years - | Instituto Nacional de Cancer, Brazil | |
| Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC | NCT00234468 | Non Small Cell ... | Iressa (Gefitin... | 18 Years - | AstraZeneca | |
| Phase I Study of Vorinostat and Sorafenib in Advanced Cancer | NCT00635791 | Malignant Solid... Renal Cell Carc... Non Small Cell ... | Sorafenib Vorinostat | 18 Years - | University of Colorado, Denver | |
| LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer | NCT01685138 | Non-Small Cell ... | LDK378 | 18 Years - | Novartis | |
| LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer | NCT01685138 | Non-Small Cell ... | LDK378 | 18 Years - | Novartis | |
| Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer | NCT06267144 | Lung Cancer | Sintilimab plus... | 18 Years - 75 Years | The First Hospital of Jilin University | |
| Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer | NCT02762877 | Non Small Cell ... | 18 Years - | Genomic Health®, Inc. | ||
| Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | NCT00080340 | Non Small Cell ... | TLK286 (Telcyta... gefitinib (Ires... | 18 Years - | Telik | |
| ZD6474 Phase IIa Dose Finding Multicentre Study | NCT00252746 | Non Small Cell ... | ZD6474 (vandeta... ZD6474 (vandeta... ZD6474 (vandeta... | 20 Years - | Sanofi | |
| Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy | NCT01209520 | Lung Cancer Non Small Cell ... Hypermethylatio... | Cisplatin Carboplatin Paclitaxel Vidaza Tumor Specimen ... Blood Sample fo... Vinorelbine Docetaxel Pemetrexed | 18 Years - | University of Miami | |
| An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations | NCT01646125 | Advanced Non Sm... | AUY922 Docetaxel Pemetrexed | 18 Years - | Novartis | |
| Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC | NCT00234468 | Non Small Cell ... | Iressa (Gefitin... | 18 Years - | AstraZeneca | |
| Texture Features and PDL1 in CT-PET 18 FDG | NCT04309422 | Non Small Cell ... | 18 Years - | University Hospital, Montpellier | ||
| Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy | NCT01209520 | Lung Cancer Non Small Cell ... Hypermethylatio... | Cisplatin Carboplatin Paclitaxel Vidaza Tumor Specimen ... Blood Sample fo... Vinorelbine Docetaxel Pemetrexed | 18 Years - | University of Miami | |
| Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients | NCT01941316 | Small Cell Lung... Non Small Cell ... Irinotecan Sens... | Carfilzomib Irinotecan | 18 Years - | Cancer Research and Biostatistics Clinical Trials Consortium | |
| SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients | NCT00608868 | Non Small Cell ... | Gefitinib | 19 Years - 80 Years | AstraZeneca | |
| Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer | NCT00592007 | Non Small Cell ... | Fulvestrant and... | 18 Years - | University of California, San Diego | |
| Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients | NCT01941316 | Small Cell Lung... Non Small Cell ... Irinotecan Sens... | Carfilzomib Irinotecan | 18 Years - | Cancer Research and Biostatistics Clinical Trials Consortium | |
| Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2 | NCT01836575 | Non Small Cell ... | Pemetrexed Carboplatin | 18 Years - | Instituto Nacional de Cancer, Brazil | |
| Protocol for Primary Fractionated Stereotactic Body Radiation Therapy for Stage T1 - T3N0 Non Small Cell Lung Carcinoma. | NCT00727350 | Non Small Cell ... | Fractionated st... | 18 Years - | AZ-VUB | |
| An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations | NCT01646125 | Advanced Non Sm... | AUY922 Docetaxel Pemetrexed | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
